We are live on ! Find out more
PETX

Aratana Therapeutics, Inc.
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

82 hedge funds and large institutions have $276M invested in Aratana Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 11 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 11

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

8% less funds holding

Funds holding: 8982 (-7)

24% less capital invested

Capital invested by funds: $364M → $276M (-$88.3M)

39% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 18

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $5K

Holders
82
Holders Change
-7
Holders Change %
-7.87%
% of All Funds
2.38%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
11
Increased
44
Reduced
11
Closed
18
Calls
Puts
$5K
Net Calls
-$5K
Net Calls Change
+$43K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$37.7M +$19.5M +1,611,700 +75%
Franklin Resources
2
Franklin Resources
California
$33.8M +$8.77M +723,615 +27%
Jennison Associates
3
Jennison Associates
New York
$30.9M +$7.74M +638,761 +26%
MAM
4
MPM Asset Management
Massachusetts
$21.3M +$303K +25,000 +1%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$15.8M +$3.64M +300,000 +24%
BC
6
Broadfin Capital
New York
$14.5M +$7.58M +625,000 +76%
Massachusetts Financial Services
7
Massachusetts Financial Services
Massachusetts
$12.5M +$3.25M +268,284 +27%
AllianceBernstein
8
AllianceBernstein
Tennessee
$11.8M +$1.12M +92,133 +8%
Vanguard Group
9
Vanguard Group
Pennsylvania
$7.34M +$2.18M +179,704 +33%
BFA
10
BlackRock Fund Advisors
California
$6.78M +$886K +73,108 +12%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$6.7M +$3.09M +255,052 +62%
HCMT
12
Highland Capital Management (Texas)
Texas
$6.62M +$7.99M +658,954 New
AWMDMG
13
Austin W. Marxe & David M. Greenhouse
New York
$6.02M
JP Morgan Chase
14
JP Morgan Chase
New York
$5.89M -$571K -47,128 -7%
O
15
OppenheimerFunds
New York
$4.59M +$1.32M +108,875 +31%
WRF
16
Waddell & Reed Financial
Kansas
$4.02M -$121K -10,000 -2%
Goldman Sachs
17
Goldman Sachs
New York
$3.19M +$194K +15,965 +5%
State Street
18
State Street
Massachusetts
$3.06M +$162K +13,362 +5%
Lazard Asset Management
19
Lazard Asset Management
New York
$3.03M +$266K +21,980 +8%
BIT
20
BlackRock Institutional Trust
California
$2.86M +$156K +12,831 +5%
Northern Trust
21
Northern Trust
Illinois
$2.67M +$1.64M +135,290 +104%
UOC
22
UBS O'Connor
Illinois
$2.5M +$2.05M +168,789 +212%
Principal Financial Group
23
Principal Financial Group
Iowa
$2.46M -$14.5K -1,200 -0.5%
EAM
24
Eagle Asset Management
Florida
$2.27M -$196K -16,186 -7%
GPGA
25
Grandeur Peak Global Advisors
Utah
$2.24M +$519K +42,825 +24%

PETX Hedge Fund Activity: Q3 2014 in Review

82 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q3 2014, worth a combined $276M — down 24% from $364M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of PETX and 11 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 44 added.

The largest buyer was Wellington Management Group, adding an estimated $19.5M. The largest seller was Deerfield Management, exiting entirely with an estimated $12.3M sold.

  • 82 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q3 2014, down from 89 in Q2 2014.
  • Funds reported $276M of Aratana Therapeutics, Inc. stock for Q3 2014, down 24% quarter-over-quarter.
  • 11 funds opened new Aratana Therapeutics, Inc. positions in Q3 2014 and 18 closed out, a net change of -7 holders.
  • The largest Aratana Therapeutics, Inc. buyer in Q3 2014 was Wellington Management Group, an estimated $19.5M added.
  • The largest Aratana Therapeutics, Inc. seller in Q3 2014 was Deerfield Management, an estimated $12.3M sold.

Based on aggregated 13F filings for Q3 2014.